Back
The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.
Journal article

The impact of the Fungus-Host-Microbiota interplay upon Candida albicans infections: current knowledge and new perspectives.

  • d'Enfert C Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur, USC 2019 INRA, 75015 Paris, France.
  • Kaune AK Aberdeen Fungal Group, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
  • Alaban LR BIOASTER Microbiology Technology Institute, 40 avenue Tony Garnier, 69007 Lyon, France.
  • Chakraborty S Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Beutenbergstraße 11a, 07745 Jena, Germany.
  • Cole N Gut Microbiology Group, Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
  • Delavy M Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur, USC 2019 INRA, 75015 Paris, France.
  • Kosmala D Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur, USC 2019 INRA, 75015 Paris, France.
  • Marsaux B ProDigest, Technologiepark 94, B-9052 Gent, Belgium.
  • Fróis-Martins R Immunology Section, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 266a, Zurich 8057, Switzerland.
  • Morelli M Mimetas, J.H. Oortweg 19, Leiden, The Netherlands.
  • Rosati D Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands.
  • Valentine M Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Beutenbergstraße 11a, 07745 Jena, Germany.
  • Xie Z Gut Microbiome Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
  • Emritloll Y Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur, USC 2019 INRA, 75015 Paris, France.
  • Warn PA Magic Bullet Consulting, London, WC2H 9JQ, UK.
  • Bequet F BIOASTER Microbiology Technology Institute, 40 avenue Tony Garnier, 69007 Lyon, France.
  • Bougnoux ME Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur, USC 2019 INRA, 75015 Paris, France.
  • Bornes S Université Clermont Auvergne, INRAE, VetAgro Sup, UMRF, 15000, Aurillac, France.
  • Gresnigt MS Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Beutenbergstraße 11a, 07745 Jena, Germany.
  • Hube B Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Beutenbergstraße 11a, 07745 Jena, Germany.
  • Jacobsen ID Microbial Immunology Research Group, Emmy Noether Junior Research Group Adaptive Pathogenicity Strategies, and the Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knöll Institute, Beutenbergstraße 11a, 07745 Jena, Germany.
  • Legrand M Unité Biologie et Pathogénicité Fongiques, Département de Mycologie, Institut Pasteur, USC 2019 INRA, 75015 Paris, France.
  • Leibundgut-Landmann S Immunology Section, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 266a, Zurich 8057, Switzerland.
  • Manichanh C Gut Microbiome Group, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
  • Munro CA Aberdeen Fungal Group, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
  • Netea MG Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Geert Grooteplein 28, 6525 GA Nijmegen, The Netherlands.
  • Queiroz K Mimetas, J.H. Oortweg 19, Leiden, The Netherlands.
  • Roget K Biose, 22 allée Alan Turing, 63000 Clermont-Ferrand, France.
  • Thomas V BIOASTER Microbiology Technology Institute, 40 avenue Tony Garnier, 69007 Lyon, France.
  • Thoral C Biose, 22 allée Alan Turing, 63000 Clermont-Ferrand, France.
  • Van den Abbeele P ProDigest, Technologiepark 94, B-9052 Gent, Belgium.
  • Walker AW Gut Microbiology Group, Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
  • Brown AJP MRC Centre for Medical Mycology, University of Exeter, Geoffrey Pope Building, Stocker Road, Exeter EX4 4QD, UK.
Show more…
  • 2020-11-24
Published in:
  • FEMS microbiology reviews. - 2020
Candida
Candida infections
antifungal immunity
fungal variability
fungus-host-microbiota interactions
microbiota
microbiota variability
mycobiota
patient variability
English Candida albicans is a major fungal pathogen of humans. It exists as a commensal in the oral cavity, gut or genital tract of most individuals, constrained by the local microbiota, epithelial barriers and immune defences. Their perturbation can lead to fungal outgrowth and the development of mucosal infections such as oropharyngeal or vulvovaginal candidiasis, and patients with compromised immunity are susceptible to life-threatening systemic infections. The importance of the interplay between fungus, host and microbiota in driving the transition from C. albicans commensalism to pathogenicity is widely appreciated. However, the complexity of these interactions, and the significant impact of fungal, host and microbiota variability upon disease severity and outcome, are less well understood. Therefore, we summarise the features of the fungus that promote infection, and how genetic variation between clinical isolates influences pathogenicity. We discuss antifungal immunity, how this differs between mucosae, and how individual variation influences a person's susceptibility to infection. Also, we describe factors that influence the composition of gut, oral and vaginal microbiotas, and how these affect fungal colonisation and antifungal immunity. We argue that a detailed understanding of these variables, which underlie fungal-host-microbiota interactions, will present opportunities for directed antifungal therapies that benefit vulnerable patients.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/22800
Statistics
Document views: 9 File downloads: